Company news
Vericel Corporation (NASDAQ:VCEL) news
Vericel Corporation news releases on 6ix. Latest, Sep 20, 2023: Vericel Announces U.S. Commercial Availability of NexoBrid® (anacaulase-bcdb)…
Press releases — page 2
Vericel Announces U.S. Commercial Availability of NexoBrid® (anacaulase-bcdb) for the Treatment of Severe Thermal Burns in Adults
September 19, 2023
Vericel to Present at the Morgan Stanley Global Healthcare Conference
September 5, 2023
Vericel Reports Second Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
August 1, 2023
Vericel to Report Second-Quarter 2023 Financial Results on August 2, 2023
July 19, 2023
Vericel Reports First Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
May 9, 2023
Vericel to Report First-Quarter 2023 Financial Results on May 10, 2023
April 25, 2023
Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Tuesday, March 7, 2023
February 27, 2023
Vericel Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Full-Year 2023 Financial Guidance
February 22, 2023
Vericel to Report Fourth-Quarter 2022 Financial Results on February 23, 2023
February 8, 2023
Vericel Announces Preliminary Fourth-Quarter and Full-Year 2022 Financial Results and Accelerated Launch Timeline for MACI Arthroscopic Program
January 9, 2023
Vericel to Present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023
January 3, 2023
Vericel Announces FDA Approval of NexoBrid for the Treatment of Severe Thermal Burns in Adults
December 28, 2022
Vericel to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum and the Stephens Annual Investment Conference
November 9, 2022
Vericel Reports Third Quarter 2022 Financial Results
November 8, 2022
Vericel to Report Third-Quarter 2022 Financial Results on November 9, 2022
October 25, 2022
Vericel to Present at the Ladenburg Thalmann Healthcare Conference
September 21, 2022
Vericel to Present at the Morgan Stanley Global Healthcare and H.C. Wainwright Global Investment Conferences
September 5, 2022
Vericel Reports Second Quarter 2022 Financial Results
August 2, 2022
MediWound Announces U.S. FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns
August 2, 2022
Vericel Announces Publication of Positive Results from Retrospective Study by the Burn and Reconstructive Centers of America (BRCA) of Patients with Large Posterior Trunk Burns Treated with Epicel
July 20, 2022
Vericel to Report Second-Quarter 2022 Financial Results on August 3, 2022
July 19, 2022
Vericel Reports First Quarter 2022 Financial Results
May 3, 2022
Vericel to Report First-Quarter 2022 Financial Results on May 4, 2022
April 19, 2022
Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on March 22, 2022
March 14, 2022
Vericel to Present at the Cowen 42nd Annual Health Care Conference on March 9, 2022
February 28, 2022
Vericel Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Full-Year 2022 Financial Guidance
February 23, 2022
Vericel Announces Appointment of Jonathan Siegal as Principal Accounting Officer
February 23, 2022
Vericel to Report Fourth-Quarter 2021 Financial Results on February 24, 2022
February 9, 2022
Vericel Announces Plans for a New State-of-the-Art Cell Therapy Manufacturing Facility to Support Long-Term Growth
February 1, 2022
Vericel to Present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022
January 3, 2022
Vericel to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health and Services Forum on November 18th, 2021
November 10, 2021
Vericel Reports Third Quarter 2021 Financial Results
November 8, 2021
Vericel to Report Third-Quarter 2021 Financial Results on November 9, 2021
October 20, 2021
Vericel to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference on September 13th, 2021
September 7, 2021
Vericel Expands Executive Leadership Team and Announces Appointment of Patrick Fowler as Senior Vice President, Corporate Development and Strategy
September 6, 2021
Vericel Reports Second Quarter 2021 Financial Results and Raises Full-Year 2021 Revenue Guidance
August 3, 2021
Vericel to Report Second-Quarter 2021 Financial Results on August 4, 2021
July 20, 2021
Vericel to Present at the Ladenburg Thalmann Healthcare Conference on Tuesday, July 13, 2021
July 6, 2021
Vericel Provides Regulatory Update for NexoBrid
June 28, 2021
MediWound Receives Complete Response Letter from U.S. FDA for NexoBrid Biologics License Application
June 28, 2021
Vericel to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference on Thursday, June 10, 2021
June 8, 2021
Vericel Announces Appointment of Lisa Wright to Board of Directors
June 1, 2021
Vericel to Present at the Canaccord Genuity Virtual Musculoskeletal Conference on Thursday, May 20, 2021
May 12, 2021
Vericel Reports First Quarter 2021 Financial Results and Raises Full-Year 2021 Revenue Guidance
May 4, 2021
Vericel to Report First-Quarter 2021 Financial Results on May 5, 2021
April 20, 2021
Vericel to Present at the 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15, 2021
April 8, 2021
Vericel to Present at the Oppenheimer 31st Annual Healthcare Conference on Wednesday, March 17, 2021
March 9, 2021
Vericel Announces Webcast of Presentation at Upcoming H.C. Wainwright Virtual Global Life Sciences Conference
March 1, 2021
Vericel Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Full-Year 2021 Financial Guidance
February 23, 2021
Vericel to Present at the SVB Leerink 10th Annual Global Healthcare Conference on Thursday, February 25, 2021
February 21, 2021